Literature DB >> 2528052

Primary dapsone chemoprophylaxis for Pneumocystis carinii pneumonia in immunocompromised patients infected with the human immunodeficiency virus.

C R Lucas1, A M Sandland, A Mijch, J M Simpson.   

Abstract

During a 12-month period from August 1, 1986 to July 31, 1987, a study of primary chemoprophylaxis with dapsone for Pneumocystis carinii pneumonia was undertaken in immunodeficient patients who were infected with the human immunodeficiency virus. One attack of P. carinii pneumonia occurred among 16 patients who received chemoprophylaxis immediately that a T-helper (CD4) lymphocyte count of less than 0.2 x 10(9)/L was recorded compared with 16 attacks in the historical control group of 46 similar patients who did not receive chemoprophylaxis (log-rank test, chi 2(1) = 3.72; P = 0.05).

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2528052     DOI: 10.5694/j.1326-5377.1989.tb128450.x

Source DB:  PubMed          Journal:  Med J Aust        ISSN: 0025-729X            Impact factor:   7.738


  3 in total

1.  Opportunistic infections in HIV-infected patients.

Authors:  S D Shafran
Journal:  Can J Infect Dis       Date:  1992-03

2.  Pharmacokinetics and safety of weekly dapsone and dapsone plus pyrimethamine for prevention of pneumocystis pneumonia.

Authors:  J Falloon; J Lavelle; D Ogata-Arakaki; A Byrne; A Graziani; A Morgan; M A Amantea; K Ownby; M Polis; R T Davey
Journal:  Antimicrob Agents Chemother       Date:  1994-07       Impact factor: 5.191

3.  Anti-Toxoplasma effects of dapsone alone and combined with pyrimethamine.

Authors:  F Derouin; C Piketty; C Chastang; F Chau; B Rouveix; J J Pocidalo
Journal:  Antimicrob Agents Chemother       Date:  1991-02       Impact factor: 5.191

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.